Associated Papers
Implications of genetic variation of common Drug Metabolizing Enzymes and ABC Transporters among the Pakistani Population.
Afsar NA et al.
Scientific Reports, 2019
Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children.
Salem AH et al.
Antimicrobial Agents and Chemotherapy, 2014
Haplotype structure and allele frequencies of CYP2B6 in Spaniards and Central Americans.
Arenaz I et al.
Fundamental & Clinical Pharmacology, 2010
Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.
Bray J et al.
British Journal of Cancer, 2010
Association of drug metabolism gene polymorphisms with toxicities, graft-versus-host disease and survival after HLA-identical sibling hematopoietic stem cell transplantation for patients with leukemia.
Rocha V et al.
Leukemia, 2009
Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects.
Robertson SM et al.
Journal of Acquired Immune Deficiency Syndromes (1999), 2008
Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.
Nakajima M et al.
Pharmacogenetics and Genomics, 2007
Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines.
Brandon EF et al.
Toxicology and Applied Pharmacology, 2006
Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.
Tsuchiya K et al.
Biochemical and Biophysical Research Communications, 2004
Select a paper to view details